Refinement of the Definition of Permissible HLA-DPB1 Mismatches with Predicted Indirectly ReCognizable HLA-DPB1 Epitopes

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1705-1710

  Thus, Kirsten A ^a   Ruizendaal, Mieke T A ^a   de Hoop, Talitha A ^a   Borst, Eric ^a   van Deutekom, Hanneke W M ^b   te Boome, Liane ^a   Kuball, Jürgen ^a   Spierings, Eric ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acute graft versus host disease; Hematopoietic stem cell transplantation; HLA DP; Indirect recognition; Mismatch; PIRCHE

Indexed keywords

CYCLOSPORIN A; EPITOPE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DPB1 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; HLA DP ANTIGEN; HLA-DPB1 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALGORITHM; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DONOR; DRUG DOSE REDUCTION; GRAFT REJECTION; HAZARD; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPE METHOD; RECIPIENT; RETROSPECTIVE STUDY; RISK FACTOR; T LYMPHOCYTE; COHORT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MALE; PROCEDURES; UNRELATED DONORS;

ADULT; COHORT STUDIES; EPITOPES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA-DP BETA-CHAINS; HUMANS; MALE; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

EID: 84908066635     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.026     Document Type: Article

References (38)

1. Shaw B.E., Potter M.N., Mayor N.P., et al. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 31:1001-1008.
2. Zino E., Frumento G., Marktel S., et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 2004, 103:1417-1424.
3. Shaw B.E., Gooley T.A., Malkki M., et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007, 110:4560-4566.
4. Shaw B.E., Gooley T., Madrigal J.A., et al. Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. Tissue Antigens 2007, 69(Suppl 1):36-41.
5. Crocchiolo R., Zino E., Vago L., et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009, 114:1437-1444.
6. Fleischhauer K., Shaw B.E., Gooley T., et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 2012, 13:366-374.
7. Amir A.L., van der Steen D.M., Hagedoorn R.S., et al. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood 2011, 118:6733-6742.
8. Liu Z., Colovai A.I., Tugulea S., et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996, 98:1150-1157.
9. Vella J.P., Vos L., Carpenter C.B., et al. Role of indirect allorecognition in experimental late acute rejection. Transplantation 1997, 64:1823-1828.
10. Ciubotariu R., Liu Z., Colovai A.I., et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998, 101:398-405.
11. Suciu-Foca N., Ciubotariu R., Itescu S., et al. Indirect allorecognition of donor HLA-DR peptides in chronic rejection of heart allografts. Transplant Proc 1998, 30:3999-4000.
12. Hornick P.I., Mason P.D., Baker R.J., et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000, 101:2405-2410.
13. Otten H.G., Calis J.J., Kesmir C., et al. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation. Hum Immunol 2013, 74:290-296.
14. Geneugelijk K., Thus K.A., Spierings E. Predicting Alloreactivity in Transplantation. J Immunol Res 2014, 2014:159479.
15. Thus K.A., Te Boome L., Kuball J., et al. Indirectly Recognized HLA-C Mismatches and Their Potential Role in Transplant Outcome. Front Immunol 2014, 5:210.
16. van Dorp S., Pirsma F., Wolfl M., et al. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009, 15:671-678.
17. Zino E., Vago L., Di T.S., et al. Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1031-1040.
18. Kesmir C., Nussbaum A.K., Schild H., et al. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 2002, 15:287-296.
19. Nielsen M., Lundegaard C., Lund O., et al. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005, 57:33-41.
20. Nielsen M., Lundegaard C., Blicher T., et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007, 2:e796.
21. Hoof I., Peters B., Sidney J., et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009, 61:1-13.
22. Buus S., Lauemoller S.L., Worning P., et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003, 62:378-384.
23. Nielsen M., Lundegaard C., Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007, 8:238.
24. Nielsen M., Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009, 10:296.
25. Nielsen M., Justesen S., Lund O., et al. NetMHCIIpan-2.0-Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 2010, 6:9.
26. Southwood S., Sidney J., Kondo A., et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998, 160:3363-3373.
27. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
28. Ossenkoppele G.J., Graveland W.J., Sonneveld P., et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004, 103:2908-2913.
29. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
30. Cornelissen J.J., van der H.B., Verhoef G.E., et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009, 113:1375-1382.
31. Lowenberg B., Ossenkoppele G.J., van P.W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
32. Lokhorst H.M., van der H.B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
33. Fleischhauer K., Locatelli F., Zecca M., et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006, 107:2984-2992.
34. Shaw B.E., Marsh S.G., Mayor N.P., et al. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 2006, 107:1220-1226.
35. Shaw B.E., Arguello R., Garcia-Sepulveda C.A., et al. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2010, 150:251-258.
36. Shaw B.E., Mayor N.P., Russell N.H., et al. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia 2010, 24:58-65.
37. Ibisch C., Gallot G., Vivien R., et al. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. Bone Marrow Transplant 1999, 23:1153-1159.
38. Shiina T., Suzuki S., Ozaki Y., et al. Super high resolution for single molecule-sequence-based typing of classical HLA loci at the 8-digit level using next generation sequencers. Tissue Antigens 2012, 80:305-316.